Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 7/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754619 | 0.89 | LIMK1 (0.51) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL24796187 | 0.89 | LIMK1 (0.46) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL17754623 | 0.87 | LIMK1 (0.55) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL24796206 | 0.86 | LIMK1 (0.47) | LIMK1EGFR | |
| SCHEMBL24795196 | 0.85 | HRH4 (0.43) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL16901973 | 0.83 | LIMK1 (0.61) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL26351585 | 0.81 | HTR2C (0.49) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL20809408 | 0.80 | LIMK1 (0.45) | LIMK1EGFR | |
| SCHEMBL25841453 | 0.80 | LIMK1 (0.56) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL23185176 | 0.79 | LIMK1 (0.52) | LIMK1CDK5CDK5R1HRH4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309394-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20220402877-A1 | ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-10957869-B2 | Organic luminescent materials containing cycloalkyl ancillary ligands | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20190103574-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING CYCLOALKYL ANCILLARY LIGANDS | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20190077818-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING FLUORINE ANCILLARY LIGANDS | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190103574-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING CYCLOALKYL ANCILLARY LIGANDS | ACAT1, ACACA, ACAT2 | LIMK1 311/4885CDK5 1014/4885CDK5R1 1625/4885 |
| US-10957869-B2 | Organic luminescent materials containing cycloalkyl ancillary ligands | ACAT1, ACACA, ACAT2 | LIMK1 311/4885CDK5 1014/4885CDK5R1 1625/4885 |
| US-20220402877-A1 | ELECTROLUMINESCENT DEVICE | MCOLN2, MCOLN1, LDHB | LIMK1 281/4885CDK5 3246/4885CDK5R1 4096/4885 |
| US-20190077818-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING FLUORINE ANCILLARY LIGANDS | FOXO1, NAA15, FOXK1 | LIMK1 742/4885CDK5 841/4885CDK5R1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.